Format

Send to

Choose Destination
See comment in PubMed Commons below
J Magn Reson Imaging. 2013 Apr;37(4):770-7. doi: 10.1002/jmri.23800.

Proton MRS in mild cognitive impairment.

Author information

1
Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA. kantarci.kejal@mayo.edu

Abstract

Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ((1)H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.

PMID:
23526756
PMCID:
PMC3609038
DOI:
10.1002/jmri.23800
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center